News Medical27d
EZH2 inhibition offers hope for fighting treatment-resistant cancers
The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...
EurekAlert!28d
Revolutionizing cancer treatment: targeting EZH2 for a new era of precision medicine
Roles of EZH2 in cancer. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases.
eLife17d
Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma
Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...
MedPage Today29d
EZH2 Inhibitor Cuts Risk of Progression in Metastatic Prostate Cancer
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In this ...
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.
Nasdaq14d
HUTCHMED Receives Conditional Approval from NMPA for TAZVERIK® as First EZH2 Inhibitor for Relapsed Follicular Lymphoma in China
HUTCHMED has received conditional approval from the National Medical Products Administration (NMPA) in China for TAZVERIK® (tazemetostat), marking it as the first EZH2 inhibitor approved in the ...